Selling and Marketing Expense of Bionik Laboratories Corp. from 30 Jun 2015 to 31 Mar 2023

Taxonomy & unit
us-gaap: USD
Description
The aggregate total amount of expenses directly related to the marketing or selling of products or services.
Summary
Bionik Laboratories Corp. quarterly and annual Selling and Marketing Expense in USD history and change rate from 30 Jun 2015 to 31 Mar 2023.
  • Bionik Laboratories Corp. Selling and Marketing Expense for the quarter ending 31 Mar 2023 was $477,010, a 18% decline year-over-year.
  • Bionik Laboratories Corp. Selling and Marketing Expense for the twelve months ending 31 Mar 2023 was $1,981,897, a 3.2% increase year-over-year.
  • Bionik Laboratories Corp. annual Selling and Marketing Expense for 2022 was $1,981,897, a 3.2% increase from 2021.
  • Bionik Laboratories Corp. annual Selling and Marketing Expense for 2021 was $1,920,749, a 87% increase from 2020.
  • Bionik Laboratories Corp. annual Selling and Marketing Expense for 2020 was $1,025,404, a 53% decline from 2019.
Source SEC data
View on sec.gov
Selling and Marketing Expense, Trailing 12 Months (USD)
Selling and Marketing Expense, Quarterly (USD)
Selling and Marketing Expense, YoY Quarterly Change (%)
Selling and Marketing Expense, Annual (USD)
Selling and Marketing Expense, YoY Annual Change (%)

Bionik Laboratories Corp. Quarterly Selling and Marketing Expense (USD)

Period TTM Value Value YoY Chg Change % Start Date End Date Report Filed Fiscal Year Fiscal Period
Q1 2023 $1,981,897 $477,010 -$108,008 -18% 01 Jan 2023 31 Mar 2023 10-K 21 Jun 2023 2023 FY
Q4 2022 $2,089,905 $446,427 -$120,873 -21% 01 Oct 2022 31 Dec 2022 10-Q 08 Feb 2023 2023 Q3
Q3 2022 $2,210,778 $496,350 +$57,393 +13% 01 Jul 2022 30 Sep 2022 10-Q 09 Nov 2022 2023 Q2
Q2 2022 $2,153,385 $562,110 +$232,636 +71% 01 Apr 2022 30 Jun 2022 10-Q 10 Aug 2022 2022 Q1
Q1 2022 $1,920,749 $585,018 +$380,607 +186% 01 Jan 2022 31 Mar 2022 10-K 21 Jun 2023 2023 FY
Q4 2021 $1,540,142 $567,300 +$240,958 +74% 01 Oct 2021 31 Dec 2021 10-Q 08 Feb 2023 2023 Q3
Q3 2021 $1,299,184 $438,957 +$183,201 +72% 01 Jul 2021 30 Sep 2021 10-Q 09 Nov 2022 2023 Q2
Q2 2021 $1,115,983 $329,474 +$90,579 +38% 01 Apr 2021 30 Jun 2021 10-Q 10 Aug 2022 2022 Q1
Q1 2021 $1,025,404 $204,411 -$319,220 -61% 01 Jan 2021 31 Mar 2021 10-K 09 Jun 2022 2022 FY
Q4 2020 $1,344,624 $326,342 -$154,492 -32% 01 Oct 2020 31 Dec 2020 10-Q 09 Feb 2022 2022 Q3
Q3 2020 $1,499,116 $255,756 -$329,019 -56% 01 Jul 2020 30 Sep 2020 10-Q 10 Nov 2021 2022 Q2
Q2 2020 $1,828,135 $238,895 -$344,837 -59% 01 Apr 2020 30 Jun 2020 10-Q 12 Aug 2021 2022 Q1
Q1 2020 $2,172,972 $523,631 -$330,305 -39% 01 Jan 2020 31 Mar 2020 10-K 24 Jun 2021 2021 FY
Q4 2019 $2,503,277 $480,834 -$34,605 -6.7% 01 Oct 2019 31 Dec 2019 10-Q 11 Feb 2021 2020 Q3
Q3 2019 $2,537,882 $584,775 +$157,450 +37% 01 Jul 2019 30 Sep 2019 10-Q 12 Nov 2020 2020 Q2
Q2 2019 $2,380,432 $583,732 +$41,073 +7.6% 01 Apr 2019 30 Jun 2019 10-Q 12 Aug 2020 2020 Q1
Q1 2019 $2,339,359 $853,936 +$177,178 +26% 01 Jan 2019 31 Mar 2019 10-K 29 Jun 2020 2020 FY
Q4 2018 $2,162,181 $515,439 +$83,179 +19% 01 Oct 2018 31 Dec 2018 10-Q 14 Feb 2020 2019 Q3
Q3 2018 $2,079,002 $427,325 -$7,969 -1.8% 01 Jul 2018 30 Sep 2018 10-Q 14 Nov 2019 2019 Q2
Q2 2018 $2,086,971 $542,659 +$97,134 +22% 01 Apr 2018 30 Jun 2018 10-Q 12 Aug 2019 2019 Q1
Q1 2018 $1,989,837 $676,758 +$135,060 +25% 01 Jan 2018 31 Mar 2018 10-K 01 Jul 2019 2019 FY
Q4 2017 $1,854,777 $432,260 +$55,214 +15% 01 Oct 2017 31 Dec 2017 10-Q 11 Feb 2019 2019 Q3
Q3 2017 $1,799,563 $435,294 +$248,029 +132% 01 Jul 2017 30 Sep 2017 10-Q 13 Nov 2018 2019 Q2
Q2 2017 $1,551,534 $445,525 +$363,327 +442% 01 Apr 2017 30 Jun 2017 10-Q 14 Aug 2018 2019 Q1
Q1 2017 $1,188,207 $541,698 +$541,698 01 Jan 2017 31 Mar 2017 10-K 27 Jun 2018 2018 FY
Q4 2016 $646,509 $377,046 +$377,046 01 Oct 2016 31 Dec 2016 10-Q 13 Feb 2018 2018 Q3
Q3 2016 $269,463 $187,265 +$187,265 01 Jul 2016 30 Sep 2016 10-Q 13 Nov 2017 2018 Q2
Q2 2016 $82,198 $82,198 +$82,198 01 Apr 2016 30 Jun 2016 10-Q 14 Aug 2017 2018 Q1
Q1 2016 $0 $0 01 Jan 2016 31 Mar 2016 8-K 21 Dec 2017
Q4 2015 $0 01 Oct 2015 31 Dec 2015 10-Q 14 Feb 2017 2017 Q3
Q3 2015 $0 01 Jul 2015 30 Sep 2015 10-Q 14 Nov 2016 2017 Q2
Q2 2015 $0 01 Apr 2015 30 Jun 2015 10-Q 15 Aug 2016 2017 Q1

Bionik Laboratories Corp. Annual Selling and Marketing Expense (USD)

Period Value YoY Chg Change % Start Date End Date Report Filed Fiscal Year Fiscal Period
2022 $1,981,897 +$61,148 +3.2% 01 Apr 2022 31 Mar 2023 10-K 21 Jun 2023 2023 FY
2021 $1,920,749 +$895,345 +87% 01 Apr 2021 31 Mar 2022 10-K 21 Jun 2023 2023 FY
2020 $1,025,404 -$1,147,568 -53% 01 Apr 2020 31 Mar 2021 10-K 09 Jun 2022 2022 FY
2019 $2,172,972 -$166,387 -7.1% 01 Apr 2019 31 Mar 2020 10-K 24 Jun 2021 2021 FY
2018 $2,339,359 +$349,522 +18% 01 Apr 2018 31 Mar 2019 10-K 29 Jun 2020 2020 FY
2017 $1,989,837 +$801,630 +67% 01 Apr 2017 31 Mar 2018 10-K 01 Jul 2019 2019 FY
2016 $1,188,207 +$1,188,207 01 Apr 2016 31 Mar 2017 10-K 27 Jun 2018 2018 FY
2015 $0 01 Apr 2015 31 Mar 2016 8-K 21 Dec 2017
* An asterisk sign (*) next to the value indicates that the value is likely invalid.